“Revenues at the midpoint, excluding COVID and LOE products, are expected to grow approximately 4% operationally year over year.”

In context

“e expect total company full year 2026 revenues to be in the range of $59.5 billion to $62.5 billion and full year 2026 adjusted diluted earnings per share to be in the range of $2.80 to $3 a share, which reflects our expectations of strong contributions across our product portfolio, mid-seventies adjusted gross margin, continued focus on strong cost management, all while prioritizing investments in our business to drive growth by the end of this decade. Our COVID products are expected to trend lower again in 2026 with revenues of approximately $5 billion. We continue to expect stable revenue contribution from our non-COVID product portfolio, which incorporates an expectation of approximately $1.5 billion in revenue compression due to products impacted by anticipated generic entry in 2026. Revenues at the midpoint, excluding COVID and LOE products, are expected to grow approximately 4% operationally year over year. And lastly, I will mention that we will continue to monitor currency fluctuations as the year progresses. In closing, let me continue to emphasize that over the next few years, our focus is on investing in key assets and managing upcoming LOEs, mainly from 2026 through 2028. At the end of the decade, growth is expected to be driven by our advancing R&D pipeline, the business development initiatives we've already executed, and the ongoing progress of products we've recently launched or acquired. Our goal is to invest strategically, balancing cost savings with funding high-value products, designed to ensure long-term and sustainable growth potential for our shareholders. And with that, I'll turn it back to Albert and begin the Q&A. Albert Bourla: Thank you, David. Congratulations for an exc”